findmyKOL

Mahnaz Mellati, MD

Basic profile

University of Washington

ORCIDNone on fileNPI
RegionSeattle, WA · WestSpecialtyEndocrinology, Diabetes & MetabolismFocusEndocrinology/Metabolic
Last active 2020findmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2020Online presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Mahnaz Mellati is an Endocrinology/Metabolic physician affiliated with University of Washington. OpenAlex indexes 9 publications with 460 citations (h-index 7).

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
9publications

Distinct works indexed by OpenAlex.

460citations

Total citations across indexed works.

7h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
16companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments

Industry payments

16 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

16 companies with payments on record in CMS Open Payments (2021 onward), matched to this physician's NPI. The itemized breakdown by company, amount and year is part of the full profile. Why? →

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Musculoskeletal

    38.8%
    RANK Ligand Inhibitor38.8%
    Denosumab100%
    Part B, office-administered11 patients
  • Metabolism & gastrointestinal

    32.7%
    GLP-1 receptor agonist11.8%
    Ozempic69%Trulicity21%Victoza 3-Pak10%
    Part D<11 patients
    Insulin Analog6.8%
    Lantus Solostar46%Basaglar Kwikpen U-10022%Toujeo Solostar12%Novolog Flexpen11%Humalog Kwikpen U-10010%
    Part D<11 patients

    + 4 more classes in this area

  • Hormonal (systemic)

    17.2%
    l-Thyroxine13%
    Levothyroxine Sodium83%Synthroid17%
    Part D71 patients
    l-Triiodothyronine1.9%
    Liothyronine Sodium100%
    Part D15 patients

    + 2 more classes in this area

Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”